Accelerating The Development And Production Of High-Quality Bispecific Antibodies

By Dongyoung Park

Bispecific antibodies (bsAbs) are a new class of drugs with the potential to revolutionize disease treatment. These next-generation drugs hold immense potential to revolutionize treatment for a vast array of diseases, including those that have defied conventional therapies. Unlike traditional antibodies that target a single molecule, bsAbs boast a unique dual specificity. This innovative approach has the potential to create more effective and targeted treatments with fewer side effects, offering hope for patients with unmet medical needs.

However, the intricate structure of bsAbs presents a significant roadblock in their development and manufacturing. Traditional methods often struggle to ensure the correct pairing of antibody chains, resulting in low yields and impurities. This not only hinders production efficiency but also raises serious concerns about the quality and efficacy of the final therapeutic product.

Samsung Biologics, a leader in contract development and manufacturing (CDMO), is at the forefront of overcoming these challenges with their groundbreaking S-DUAL™ platform. This ingenious technology employs a clever combination of a knob-in-hole design and an asymmetric antibody structure. This approach guarantees an impressive 99% pairing success rate, significantly enhancing the production of high-quality bsAbs.

Delve into a compelling case study that showcases the power of the S-DUAL™ platform. Researchers optimized the upstream process for bsAb production using this innovative technology. The optimized process not only achieved a remarkable 3-fold increase in productivity but also demonstrated a dramatic improvement in lactate metabolism, a critical indicator of cell health and process efficiency.